Month: September 1985

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

HTLV-III/LAV antibody status of spouses and household contacts assisting in home infusion of hemophilia patients

by

Abstract

Thirty-four adult and pediatric hemophilia A and B patients and 50 nonhemophilic members belonging to 28 families were enrolled in August 1984 in a study of human T cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) antibody status and T cell subpopulation numbers.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome

by

Abstract

During the period of 1979 to 1983, 38 patients with cystic fibrosis (CF) at the CF center of St. Christopher’s Hospital for Children in Pennsylvania developed respiratory tract colonization with Pseudomonas cepacia. Seventeen (45%) of the patients with colonization died.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate

by

Abstract

Evidence for exposure to lymphadenopathy-associated virus (LAV) was investigated in 48 patients with hemophilia, 15 of whom had been treated exclusively with single-donor cryoprecipitate. The prevalence of antibodies to LAV in all patients was 53% in 1983 and 63% in 1984, while in patients treated only with cryoprecipitate, the prevalence was 31% in 1983 and 40% in 1984.… Read more